Clinical Trials
29 trialsROTATE
Yale University
MonumenTAL-1
Janssen Research & Development, LLC
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
MonumenTAL-1
Janssen Research & Development, LLC
MonumenTAL-2
Janssen Research & Development, LLC
MajesTEC-7
Janssen Research & Development, LLC
Talisman
Janssen Research & Development, LLC
MonumenTAL-8
Janssen Research & Development, LLC
aMMbition
Janssen Research & Development, LLC
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
MonumenTAL-3
Janssen Research & Development, LLC
MAGENTA
Massachusetts General Hospital
Talquetamab in Patients With Refractory Generalized Myasthenia Gravis
First Affiliated Hospital of Chongqing Medical University
IFm2022-01
Nantes University Hospital
BLOOD-dose
Rigshospitalet, Denmark
MonumenTAL-6
Janssen Research & Development, LLC
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
KarMMa-2
Celgene
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Memorial Sloan Kettering Cancer Center
REVIVE
University of Miami
RedirecTT-1
Janssen Research & Development, LLC
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Medical College of Wisconsin
HD10/DSMMXX
University of Heidelberg Medical Center
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Icahn School of Medicine at Mount Sinai
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
City of Hope Medical Center
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Stanford University
TALTEC
North Estonia Medical Centre